Parkman Healthcare Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Parkman Healthcare Partners’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,203,484	Closed	-$7.03M	–	98
2022 Q4	$7.03M	Buy	1,203,484 +65,897	+6%	+$347K	1.87%	15
2022 Q3	$7.62M	Buy	1,137,587 +13,515	+1%	+$81.9K	2.17%	15
2022 Q2	$4.73M	Buy	1,124,072 +746,673	+198%	+$2.95M	1.74%	21
2022 Q1	$1.27M	Buy	+377,399	New	+$1.2M	0.37%	59
2021 Q1	–	Sell	-50,290	Closed	-$636K	–	100
2020 Q4	$636K	Buy	+50,290	New	+$573K	0.16%	79

Parkman Healthcare Partners's CNCE Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,203,484 shares — an estimated $7.03M sold.

Parkman Healthcare Partners first reported a position in CNCE in Q4 2020 and held it in 5 quarters. The position peaked at $7.62M in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Parkman Healthcare Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 1,203,484 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.03M.
Parkman Healthcare Partners first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 5 quarters.
Parkman Healthcare Partners's Concert Pharmaceuticals, Inc. position peaked at $7.62M in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.